← Back to Search

SpeechVive for Parkinson's Disease

N/A
Waitlist Available
Led By Kelly Richardson, Ph.D.
Research Sponsored by University of Massachusetts, Amherst
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline after 8 weeks of treatment
Awards & highlights

Study Summary

This study is evaluating whether two different behavioral treatments may help improve communication in individuals with Parkinson's disease.

Eligible Conditions
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline after 8 weeks of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline after 8 weeks of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessing Mental and Physical Effort Associated With Each Treatment Program Using the Modified National Aeronautics and Space Administration (NASA)-Task Load Index
Treatment-related Changes in Speech Breathing Will be Assessed Using Laryngeal Aerodynamics (MFDR)
Treatment-related Changes in Speech Breathing Will be Assessed Using Laryngeal Aerodynamics (Open Quotient)
+2 more
Secondary outcome measures
Treatment-related Changes in Activities of Daily Living Assessed by the Voice-related Quality of Life (VR-QOL) Questionnaire
Treatment-related Changes in Communicative Competence Will be Assessed Using the Communicative Participation Item Bank-Short Form Questionnaire
Treatment-related Changes in Quality of Life Will be Assessed Using the Parkinson's Disease Questionnaire (PDQ-39)
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: SpeechViveExperimental Treatment1 Intervention
Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
Group II: Lee Silverman Voice TreatmentExperimental Treatment1 Intervention
Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
Group III: ControlActive Control1 Intervention
Persons with Parkinsons disease do not receive voice intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lee Silverman Voice Treatment
2018
N/A
~40
SpeechVive
2018
N/A
~40

Find a Location

Who is running the clinical trial?

University of Massachusetts, AmherstLead Sponsor
78 Previous Clinical Trials
467,736 Total Patients Enrolled
Purdue UniversityOTHER
226 Previous Clinical Trials
72,848 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
330 Previous Clinical Trials
178,435 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Voice Treatment for Parkinson's Disease
Kelly Richardson 2018. "Voice Treatment for Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03700684.
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top